GC203 ni uburyo bushya bwo kuvura bwa TIL butarimo virusi bwakozwe hifashishijwe urubuga rwo kwagura uturemangingo twa Juncell Therapeutics rwa DeepTIL® hamwe na urubuga rwo guhindura uturemangingo twa NovaGMP®. DeepTIL® ituma TIL ziba zikomeye ku buryo nta IL-2 ikenewe nyuma yo guterwa, kandi imbaraga zo kuvura mbere zishobora kuba nke. NovaGMP® ihindura uturemangingo twa T ku buryo bunoze cyane nk'ubwa Lentiviral vector mu buryo bw'ubukungu. GC203 yakozwe hifashishijwe interleukin-7 yihuza na membrane-bound, ishobora gukomeza imiterere y'uturemangingo twa T, ikanguza uturemangingo tw'umubiri w'imbere kandi ikarinda uburozi bw'umubiri.
Abashakashatsi bapimye GC203 ku barwayi basanzwe barwaye kanseri y'intanga ngore isubira, hatabayeho gufata IL-2 cyangwa gukoresha lymphodepletion ikomeye. Intego y'ubushakashatsi kwari ukumenya umutekano n'ubushobozi bw'ubu buryo bwo kuvura. Abarwayi 20 bose hamwe biyandikishije hagati ya 09/2021 na 01/2024 mu igerageza ryakozwe mu kigo kimwe, aho abarwayi 18 bapimwe. Abarwayi bapimwe bari bafite ECOG PS ya 1 (55.6%) cyangwa 2 (44.4%) kandi bahawe impuzandengo y'imiti 5 yabanje kuvura (intera: 2-11). Abarwayi 9 (50%) bari bafite ibibyimba 3 cyangwa birenga. Ingano y'ibibyimba byari 57 (intera: 13-146) mm.
GC203 yagaragaje ibisubizo bishimishije ku barwayi ba kanseri y'intanga isubira cyangwa itera kanseri y'intanga. Umutekano warushijeho kuba mwiza ugereranije n'ubuvuzi busanzwe bwa TIL, bitewe no kuvura mbere y'uko havurwa mu buryo buke no gukuraho IL-2. Ibyinshi mu bintu bibi (AEs) byari ibya 1 cyangwa ibya 2 kandi byashoboraga kugabanuka cyangwa gukira hakoreshejwe uburyo bwo kuvura ibimenyetso. Nta kintu cyabaye cya 5 cyabaye. Ku itariki ntarengwa yo ku wa 01/2024, igipimo cy'igisubizo cy'intego (ORR) cyasuzumwe n'umushakashatsi cyari 33.3% (95% CI: 16.3 - 56.3), harimo na 11.1% by'igisubizo cyuzuye (CR). Igipimo cyo Kurwanya Indwara (DCR) cyari 83.3% (95% CI, 60.8 - 94.2). Kandi igipimo cy'amezi 12 cyo kubaho (OS) cyari 68.8% (95% CI: 49.3 - 95.9). Igipimo cy'igisubizo cy'inyongera (OS) nticyari cyakuze nkuko amakuru yagabanyijwe.
Mu 2023, Madamu H yajyanywe mu bitaro mu 2023 kubera ikibazo cyo mu ndan'ububabare bwo mu kibunoNyuma yo gusuzumwa, hagaragaye ko hari uduce twinshi twa lymph nodes twagutse mu gice cyo hagati cy’inyuma, mu gituza no mu tundi duce, byemeza ko yanduye kanseri y’intanga ngabo yo mu rwego rwo hejuru. Bityo Madamu H yagizwe imiti igabanya ubukana bw’uturemangingo, abagwa, abarwayi b’umubiri, n’ibindi, ariko ingaruka ntizari nziza, kandi ikibyimba cyarongeye kugaruka.
Kubera iyo mpamvu, Madamu H yitabiriye igerageza rya TIL cell therapy GC203, kandi nyuma y'ukwezi kumwe avurwa na GC203, ikibyimba cyagabanutseho 37.3%.
Umwanzuro: Gutera GC203ifite umutekano ukwiye kandi ifite akamaro gakomeye ku barwayi ba OC basubira mu bitaro kandi bafite uburyo buke bwo kuvurwa.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Amareferensi
1.https://www.juncell.com/academic-achievements
2.https://www.juncell.com/company-news-76
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5552
4.http://myimm.net/mianyizhiliao/2037.html
Igihe cyo kohereza: Ukuboza 11-2024